Publications by authors named "Katja Brouzou"
Article Synopsis
- Fingolimod (FTY) is a treatment for relapsing remitting multiple sclerosis (RRMS), but can cause severe lymphopenia, leading to the need to stop the therapy to prevent serious side effects.
- Stopping FTY can result in a severe reactivation of the disease, characterized by tumefactive demyelinating lesions (TDLs), which are large lesions in the brain possibly caused by the influx of activated lymphocytes.
- A case study of a 26-year-old woman demonstrated a major rebound of TDLs after stopping FTY, requiring multiple plasmapheresis treatments and subsequent use of ocrelizumab for long-term management.
The Marburg variant of multiple sclerosis (Marburg MS) is the most aggressive form of MS, often leading to death soon after onset. Here we describe the case of a 26-year-old Marburg MS patient presenting with severe neurological deficits requiring intensive care. In spite of more than 100 gadolinium-enhancing MRI lesions, the patient recovered almost completely upon high-dose cyclophosphamide (HiCy) rescue treatment (four consecutive days with 50 mg/kg/day, cumulative absolute dose of 14 g).
View Article and Find Full Text PDF